AML1B transcriptional repressor function is impaired by the Flt3-internal tandem duplication

British Journal of Haematology

Volumn 130, Issue 3, 2005, Pages 428-436

  Takahashi, Shinichiro ^a   Harigae, Hideo ^a   Kameoka, Junichi ^a   Sasaki, Takeshi ^a   Kaku, Mitsuo ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

AML1B; Flt3 ITD; Mammalian two hybrid assays; SMRT; Transcriptional repression

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; FLT3 LIGAND; HISTONE DEACETYLASE; ONCOPROTEIN; PROTEIN AML1B; TRANSCRIPTION FACTOR GAL4; TRANSCRIPTION FACTOR RUNX1; TRICHOSTATIN A; UNCLASSIFIED DRUG; CD135 ANTIGEN; DNA BINDING PROTEIN; FLT3 PROTEIN, HUMAN; FLT3 PROTEIN, MOUSE; MESSENGER RNA; NUCLEAR RECEPTOR CO REPRESSOR 2; NUCLEAR RECEPTOR CO-REPRESSOR 2; PROTEIN TYROSINE KINASE; REPRESSOR PROTEIN; RUNX1 PROTEIN, HUMAN; RUNX1 PROTEIN, MOUSE; TRANSCRIPTION FACTOR;

ANIMAL CELL; ARTICLE; ASSAY; ENZYME ACTIVITY; GENE OVEREXPRESSION; GENE REPRESSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; TWO HYBRID SYSTEM; ACUTE DISEASE; ANIMAL; CELL STRAIN COS1; GENE DUPLICATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; MOUSE; MYELOID LEUKEMIA; TANDEM REPEAT;

ACUTE DISEASE; ANIMALS; CORE BINDING FACTOR ALPHA 2 SUBUNIT; COS CELLS; DNA-BINDING PROTEINS; FMS-LIKE TYROSINE KINASE 3; GENE DUPLICATION; HUMANS; LEUKEMIA, MYELOID; MICE; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; REPRESSOR PROTEINS; RNA, MESSENGER; TANDEM REPEAT SEQUENCES; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 24944584218     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05621.x     Document Type: Article

References (43)

1. Aronson B.D. Fisher A.L. Blechman K. Caudy M. Gergen J.P. (1997) Groucho-dependent and -independent repression activities of Runt domain proteins. Molecular and Cellular Biology, 17, 5581 5587.
2. Espinosa L. Ingles-Esteve J. Robert-Moreno A. Bigas A. (2003) IkappaBalpha and p65 regulate the cytoplasmic shuttling of nuclear corepressors: cross-talk between notch and NFkappaB pathways. Molecular Biology of the Cell, 14, 491 502.
3. Gelmetti V. Zhang J. Fanelli M. Minucci S. Pelicci P.G. Lazar M.A. (1998) Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Molecular and Cellular Biology, 18, 7185 7191.
4. Gilliland D.G. Griffin J.D. (2002) The roles of FLT3 in hematopoiesis and leukemia. Blood, 100, 1532 1542.
5. Harper J.W. Adami G.R. Wei N. Keyomarsi K. Elledge S.J. (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75, 805 816.
6. Hayakawa F. Towatari M. Kiyoi H. Tanimoto M. Kitamura T. Saito H. Naoe T. (2000) Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene, 19, 624 631.
7. Hohaus S. Petrovick M.S. Voso M.T. Sun Z. Zhang D.E. Tenen D.G. (1995) PU.1 (Spi-1) and C/EBP alpha regulate expression of the granulocyte-macrophage colony-stimulating factor receptor alpha gene. Molecular and Cellular Biology, 15, 5830 5845.
8. Hug B.A. Ahmed N. Robbins J.A. Lazar M.A. (2004) A chromatin immunoprecipitation screen reveals protein kinase Cbeta as a direct RUNX1 target gene. Journal of Biological Chemistry, 279, 825 830.
9. Keeshan K. Mills K.I. Cotter T.G. McKenna S.L. (2001) Elevated Bcr-Abl expression levels are sufficient for a haematopoietic cell line to acquire a drug-resistant phenotype. Leukemia, 15, 1823 1833.
10. Kelly L.M. Liu Q. Kutok J.L. Williams I.R. Boulton C.L. Gilliland D.G. (2002a) FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood, 99, 310 318.
11. Kelly L.M. Kutok J.L. Williams I.R. Boulton C.L. Amaral S.M. Curley D.P. Ley T.J. Gilliland D.G. (2002b) PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proceedings of the National Academy of Sciences of the United States of America, 99, 8283 8288.
12. Kiyoi H. Ohno R. Ueda R. Saito H. Naoe T. (2002) Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene, 21, 2555 2563.
13. Levanon D. Negreanu V. Bernstein Y. Bar-Am I. Avivi L. Groner Y. (1994) AML1, AML2, and AML3, the human members of the runt domain gene-family: cDNA structure, expression, and chromosomal localization. Genomics, 23, 425 432.
14. Liu Y. Martindale J.L. Gorospe M. Holbrook N.J. (1996) Regulation of p21WAF1/CIP1 expression through mitogen-activated protein kinase signaling pathway. Cancer Research, 56, 31 35.
15. Lutterbach B. Westendorf J.J. Linggi B. Isaac S. Seto E. Hiebert S.W. (2000) A mechanism of repression by acute myeloid leukemia-1, the target of multiple chromosomal translocations in acute leukemia. Journal of Biological Chemistry, 275, 651 656.
16. Michieli P. Chedid M. Lin D. Pierce J.H. Mercer W.E. Givol D. (1994) Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Research, 54, 3391 3395.
17. Miyoshi H. Ohira M. Shimizu K. Mitani K. Hirai H. Imai T. Yokoyama K. Soeda E. Ohki M. (1995) Alternative splicing and genomic structure of the AML1 gene involved in acute myeloid leukemia. Nucleic Acids Research, 23, 2762 2769.
18. Mizuki M. Schwable J. Steur C. Choudhary C. Agrawal S. Sargin B. Steffen B. Matsumura I. Kanakura Y. Bohmer F.D. Muller-Tidow C. Berdel W.E. Serve H. (2003) Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood, 101, 3164 3173.
19. Nagata T. Gupta V. Sorce D. Kim W.Y. Sali A. Chait B.T. Shigesada K. Ito Y. Werner M.H. (1999) Immunoglobulin motif DNA recognition and heterodimerization of the PEBP2/CBF Runt domain. Nature Structural Biology, 6, 615 619.
20. Ogawa E. Maruyama M. Kagoshima H. Inuzuka M. Lu J. Satake M. Shigesada K. Ito Y. (1993) PEBP2/PEA2 represents a family of transcription factors homologous to the products of the Drosophila runt gene and the human AML1 gene. Proceedings of the National Academy of Sciences of the United States of America, 90, 6859 6863.
21. Okuda T. van Deursen J. Hiebert S.W. Grosveld G. Downing J.R. (1996) AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell, 84, 321 330.
22. Ozeki K. Kiyoi H. Hirose Y. Iwai M. Ninomiya M. Kodera Y. Miyawaki S. Kuriyama K. Shimazaki C. Akiyama H. Nishimura M. Motoji T. Shinagawa K. Takeshita A. Ueda R. Ohno R. Emi N. Naoe T. (2004) Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood, 103, 1901 1908.
23. Platanias L.C. (2004) SMRT interactions, repression, and Flt3-ITD. Blood, 103, 4382.
24. Rosnet O. Mattei M.G. Marchetto S. Birnbaum D. (1991) Isolation and chromosomal localization of a novel FMS-like tyrosine kinase gene. Genomics, 9, 380 385.
25. Schnittger S. Schoch C. Dugas M. Kern W. Staib P. Wuchter C. Loffler H. Sauerland C.M. Serve H. Buchner T. Haferlach T. Hiddemann W. (2002) Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood, 100, 59 66.
26. Sherr C.J. Roberts J.M. (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes & Development, 13, 1501 1512.
27. Spiekermann K. Dirschinger R.J. Schwab R. Bagrintseva K. Faber F. Buske C. Schnittger S. Kelly L.M. Gilliland D.G. Hiddemann W. (2003) The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. Blood, 101, 1494 1504.
28. Takahashi S. Licht J.D. (2002) The human promyelocytic leukemia zinc finger gene is regulated by the Evi-1 oncoprotein and a novel guanine-rich site binding protein. Leukemia, 16, 1755 1762.
29. Takahashi S. Furuyama K. Kobayashi A. Taketani S. Harigae H. Yamamoto M. Igarashi K. Sasaki T. Hayashi N. (2000) Cloning of a coproporphyrinogen oxidase promoter regulatory element binding protein. Biochemical and Biophysical Research Communications, 273, 596 602.
30. Takahashi S. McConnell M.J. Harigae H. Kaku M. Sasaki T. Melnick A.M. Licht J.D. (2004a) The Flt3 internal tandem duplication mutant inhibits the function of transcriptional repressors by blocking interactions with SMRT. Blood, 103, 4650 4658.
31. Takahashi S. Harigae H. Kaku M. Sasaki T. Licht J.D. (2004b) Flt3 mutation activates p21(WAF1/CIP1) gene expression through the action of STAT5. Biochemical and Biophysical Research Communications, 316, 85 92.
32. Takahashi S. Harigae H. Ishii K. Inomata M. Fujiwara T. Yokoyama H. Ishizawa K. Kameoka J. Licht J. Sasaki T. Kaku M. (2005) Over-expression of Flt3 induces NF-kB pathway and increases the expression of IL-6. Leukemia Research, 29, 893 899.
33. Tanaka T. Tanaka K. Ogawa S. Kurokawa M. Mitani K. Nishida J. Shibata Y. Yazaki Y. Hirai H. (1995) An acute myeloid leukemia gene, AML1, regulates hemopoietic myeloid cell differentiation and transcriptional activation antagonistically by two alternative spliced forms. The EMBO Journal, 14, 341 350.
34. Thiede C. Steudel C. Mohr B. Schaich M. Schakel U. Platzbecker U. Wermke M. Bornhauser M. Ritter M. Neubauer A. Ehninger G. Illmer T. (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood, 99, 4326 4335.
35. Uchida H. Zhang J. Nimer S.D. (1997) AML1A and AML1B can transactivate the human IL-3 promoter. Journal of Immunology, 158, 2251 2258.
36. Whitman S.P. Archer K.J. Feng L. Baldus C. Becknell B. Carlson B.D. Carroll A.J. Mrozek K. Vardiman J.W. George S.L. Kolitz J.E. Larson R.A. Bloomfield C.D. Caligiuri M.A. (2001) Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Research, 61, 7233 7239.
37. Wong C.W. Privalsky M.L. (1998) Transcriptional repression by the SMRT-mSin3 corepressor: multiple interactions, multiple mechanisms, and a potential role for TFIIB. Molecular and Cellular Biology, 18, 5500 5510.
38. Yan M. Burel S.A. Peterson L.F. Kanbe E. Iwasaki H. Boyapati A. Hines R. Akashi K. Zhang D.E. (2004) Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development. Proceedings of the National Academy of Sciences of the United States of America, 101, 17186 17191.
39. Yokota S. Kiyoi H. Nakao M. Iwai T. Misawa S. Okuda T. Sonoda Y. Abe T. Kahsima K. Matsuo Y. Naoe T. (1997) Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia, 11, 1605 1609.
40. Zhang D.E. Fujioka K. Hetherington C.J. Shapiro L.H. Chen H.M. Look A.T. Tenen D.G. (1994a) Identification of a region which directs the monocytic activity of the colony-stimulating factor 1 (macrophage colony-stimulating factor) receptor promoter and binds PEBP2/CBF (AML1). Molecular and Cellular Biology, 14, 8085 8095.
41. Zhang H. Hannon G.J. Beach D. (1994b) p21-containing cyclin kinases exist in both active and inactive states. Genes & Development, 8, 1750 1758.
42. Zhang W. Kornblau S.M. Kobayashi T. Gambel A. Claxton D. Deisseroth A.B. (1995) High levels of constitutive WAF1/Cip1 protein are associated with chemoresistance in acute myelogenous leukemia. Clinical Cancer Research, 1, 1051 1057.
43. Zheng R. Friedman A.D. Small D. (2002) Targeted inhibition of FLT3 overcomes the block to myeloid differentiation in 32Dcl3 cells caused by expression of FLT3/ITD mutations. Blood, 100, 4154 4161.